老百姓大药房（603883）标普全球、路孚特ESG评分稳定提升

Core Viewpoint - The company has received high ESG scores from S&P Global and Refinitiv, indicating strong performance in sustainability practices and positioning it as a leader among private pharmaceutical retail enterprises in China [1][2]. Group 1: ESG Ratings - S&P Global has assigned an ESG score of 24, marking two consecutive years of growth, while Refinitiv's score has increased to 59, both ranking the company first among private listed pharmaceutical retailers in China [1]. - The S&P Global Corporate Sustainability Assessment (CSA) is recognized as one of the largest annual evaluations of corporate sustainability practices, providing critical data for investment decisions [1]. Group 2: Strategic Commitment to ESG - The company emphasizes the integration of ESG principles into its operations, establishing a three-tier governance structure with a dedicated Strategic and ESG Committee [2]. - The company has committed to disclosing its corporate social responsibility reports for ten consecutive years, with the 2023 and 2024 reports upgraded to ESG reports [2]. Group 3: Social Responsibility and Community Impact - The company operates over 15,000 stores across 18 provincial markets, creating nearly 60,000 job opportunities and actively engaging in social responsibility initiatives, including donations exceeding 100 million yuan [2]. - The company aims to foster a fair and transparent business environment while contributing to green and coordinated social development [2].